Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Anti-tuberculosis Drug Resistance in the World
Multidrug-resistant tuberculosis (MDR-TB) has been recorded at the highest rates ever, according to this new report that presents findings from the largest survey to date on the scale of drug resistance in tuberculosis. This fourth global report is based on information collected between 2002 and 2006 on 90,000 TB patients in 81 countries. It also found that extensively drug-resistant tuberculosis (XDR-TB), a virtually untreatable form of the respiratory disease, has been recorded in 45 countries. The primary aim of this report is to share survey and surveillance data on drug resistance in TB. The data presented here are supplied largely by the program managers who have led the work on surveys, but also heads of reference laboratories as well as principle investigators that may have been hired to assist the national Tuberculosis Program with the study.
Fourth WHO consultation on the translation of tuberculosis research into global policy guidelines
The Global Tuberculosis Programme of the World Health Organization has the mandate to develop and disseminate evidence-based policy for tuberculosis prevention, diagnosis, treatment, and care. Regular review of evidence, and assessment of country needs for policy across the cascade of care is part of its core function. In this regard, GTB organized a fourth consultation assembling scientists, public health experts, partners, civil society, and countries to exchange views on emerging areas of need for evidence and for global TB policy guidance to achieve the goals and targets of the WHO End TB Strategy. The present report summarizes the outcome of this meeting.
Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020
Recent developments in TB treatment have prompted the need for revision of the TB treatment outcome definitions. An online expert consultation meeting organized by WHO’s Global TB Programme in November 2020 was to determine recent changes in TB treatment affecting treatment outcome definitions and discuss options for changing the definitions. The consultation led WHO to propose new treatment outcome definitions for drug-susceptible TB (DS-TB) and drug-resistant TB (DR-TB). The purpose of this publication is to summarise changes in the definitions of tuberculosis treatment outcomes, arising after the expert consultation. The publication is to inform a wide audience about the new definitions of TB treatment outcomes so that these definitions are readily adopted and used, globally.
WHO operational handbook on tuberculosis. Module 4
Operational handbook on tuberculosis. Module 4: Treatment of drug-resistant tuberculosis treatment, is a derivative product arising from the guideline on the same topic. This operational handbook is designed to facilitate implementation of the policy at country level. The target audience includes, implementing partners, programme managers, clinicians and other stakeholders engaged in TB care. The 2022 updated version of the operational handbook includes a new section stemming from the most recent round of guidelines development – the recommendation for 6-month regimen, and a new composition of the 9-month regimen for the treatment of DR-TB. Besides, the updated operational handbook includes three new web annexes: Tuberculosis medicines information sheets, management of adverse events and Active TB drug safety monitoring and management (aDSM).
